Emyria (ASX:EMD) offers new hope to Australia’s PTSD non-responders
January 10, 2024ASX-listed biotech company Emyria will offer a new treatment for thousands of Australians suffering from post-traumatic stress disorder following approval to prescribe MDMA.
Emyria’s Authorised Prescriber program sets a new standard for the treatment of PTSD and underscores the company’s commitment to providing safe and effective mental health care for patients in need.
The company’s key specialist has been granted “Authorised Prescriber” approval from the TGA.
The authorisation will enable the Australian clinical services and drug development company to prescribe stimulant and psychedelic drug MDMA, most well known as the active ingredient commonly found in ‘ecstasy’ pills, as assisted therapy for the treatment of Post-Traumatic Stress Disorder (PTSD) in Australia.
The TGA-overseen treatment is showing welcome promise to more than one-third of around a million Australians failing to benefit from conventional therapies,
The assisted therapy is being evaluated as a treatment for PTSD, and MAPS has conducted multiple Phase 3 clinical trials in the USA.
Emyria is currently studying assisted therapy for PTSD in an ethics-approved clinical trial, and the experience with the trial has informed a unique delivery model for Emyria’s Authorised Prescriber program.
Authorised Prescribers must adhere to stringent TGA guidelines to ensure the highest patient care and safety level.
The authorisation is part of Emyria’s broader commitment to increasing options for mental health through robust clinical research and ethical practice.
“This authorisation demonstrates Emyria’s commitment to evaluating emerging treatments within the strict regulatory framework set by the TGA,” Emyria CEO and MD Dr. Michael Winlo said.
“Emyria’s expertise and track record in innovative clinical service development and Real-World Data capture uniquely positions us to evaluate new therapeutic options safely and responsibly.
“Achieving Authorised Prescriber status showcases Emyria’s capacity for impactful and responsible growth in the field of mental health treatments.”
Please note the following valuable information before using this website.
Independent Research
Market Open Australia is intended to be used only for educational and informative purposes, and any information on this website should not be taken as investment advice or guidance. It is important to conduct your own research before making any investment decisions, which should be based on your own investment needs and personal circumstances. Any investment decisions based on information contained on this website should be taken in line with independent financial advice from a qualified professional or should be independently researched and verified.
